...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of dermatology >Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab
【24h】

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

机译：玛沙骨化醇软膏对接受阿达木单抗治疗的牛皮癣患者皮肤病变的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adalimumab is a biologic that is very effective for treatment of psoriasis. However, recalcitrant or recurrent lesions sometimes occur during treatment. Maxacalcitol is an active vitamin D3 ointment that is effective in treatment of psoriasis. Topical therapy may be beneficial in treatment of recalcitrant or recurrent lesions during treatment with systemic therapy, but there is little evidence on this topic. We investigated the effect of maxacalcitol on skin lesions during treatment with adalimumab in patients with psoriasis. Twelve patients with psoriasis were randomly assigned to two groups after informed consent - treatment with adalimumab only (n = 6), and treatment with adalimumab and maxacalcitol (n = 6) - and they were evaluated every 4 weeks for 44 weeks. Exacerbation was defined as an increase of the Psoriasis Area and Severity Index (PASI) score. The interval between adalimumab treatments was elongated to 3-4 weeks from 2 weeks according to the individual patient's condition. The PASI score was evaluated every 4 weeks, and the frequency of exacerbations was counted. The overall improvement in PASI score was not statistically different between the two groups, but the frequency of exacerbations was significantly less in the maxacalcitol combination group compared with the adalimumab monotherapy group (Mann-Whitney U-test, P < 0.05). The better control of skin lesions in patients who elongated the interval of adalimumab administration was achieved in the maxacalcitol combination group compared with the adalimumab monotherapy group. Topical maxacalcitol treatment is effective and useful in controlling skin lesions in patients with psoriasis when used in combination with adalimumab.
机译：阿达木单抗是一种对牛皮癣非常有效的生物制剂。但是，在治疗期间有时会出现顽固性或复发性病变。 Maxacalcitol是一种活性维生素D3软膏，可有效治疗牛皮癣。在全身性治疗期间，局部治疗可能对顽固性或复发性病变的治疗有益，但有关该主题的证据很少。我们调查了牛皮癣患者使用阿达木单抗治疗期间马沙骨化醇对皮肤损伤的影响。在知情同意后，将十二名牛皮癣患者随机分为两组-仅使用阿达木单抗治疗（n = 6），以及使用阿达木单抗和马沙骨化醇治疗（n = 6）-每4周评估一次，持续44周。恶化定义为牛皮癣面积和严重程度指数（PASI）得分的增加。根据患者的具体情况，阿达木单抗治疗之间的间隔从2周延长至3-4周。每4周评估一次PASI评分，并计算病情加重的次数。两组之间PASI评分的总体改善无统计学差异，但与adalimumab单药治疗组相比，maxacalcitol联合治疗组加重发作的频率明显减少（Mann-Whitney U检验，P <0.05）。与阿达木单抗单药治疗组相比，马沙骨化醇联合治疗组延长了阿达木单抗给药间隔的患者对皮肤病变的更好控制。当与阿达木单抗组合使用时，局部用马沙骨化醇治疗在控制牛皮癣患者的皮肤病变方面有效且有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号